[
  {
    "ts": "2025-11-10T03:17:34+00:00",
    "headline": "Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?",
    "summary": "In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-down-9-6-031734830.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "83b6320f-a359-3ccc-9dce-cafa25ba576c",
      "content": {
        "id": "83b6320f-a359-3ccc-9dce-cafa25ba576c",
        "contentType": "STORY",
        "title": "Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?",
        "description": "",
        "summary": "In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...",
        "pubDate": "2025-11-10T03:17:34Z",
        "displayTime": "2025-11-10T03:17:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-down-9-6-031734830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-down-9-6-031734830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]